KRTAP19-3

Across TCGA pan-cancer cohorts, KRTAP19-3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRTAP19-3 data layer compared with 11 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher KRTAP19-3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP19-3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

STAD, PRAD, and UCEC are the cancer types where KRTAP19-3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.169	0.730	<.001	18	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
COAD	OS	Median	All	0.202	0.806	.006	6	view →
HNSC	DFS	Median	All	1.000	0.316	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRTAP19-3–STAD (OS)

Open the STAD breakdown →